



FOR IMMEDIATE RELEASE

CONTACT INFORMATION:

Dan Dunlop, President, Jennings ddunlop@jenningsco.com
Lauren Whaley, Account Leader, Jennings lwhaley@jenningsco.com
Jennings: 919-929-0225

Entegriion CEO and president named 2008 Impact Business Leader for the Triangle

Research Triangle Park, N.C., March 3, 2008 –Stan Eskridge, CEO and president of Entegriion, joins twenty-four distinguished professionals as *Triangle Business Leader* magazine's 2008 Impact Business Leaders of the Triangle. The Impact Business Leaders were chosen from more than 180 nominations, and are recognized for their notable achievements and contributions to the Triangle business community.

The Triangle's top business leaders will be recognized at the Triangle Hall of Fame Gala to be held on the evening of March 3, at the North Raleigh Hilton. Many of the area's top leaders will be in attendance and keynote speakers for the event include: Business Leader of the Year, Bob Greczyn, president and CEO of Blue Cross Blue Shield NC; and Entrepreneurs of the Year, Susan and Richard Casey, founders of Square 1 Bank.

"I am truly honored to be recognized as one of the Triangle's business leaders," says Stan Eskridge who became Entegriion's CEO and president in 2006. "To even be considered for this list of renowned business professionals is an award in itself."

About Entegriion

Entegriion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, wound management, and associated tissue repair. The company is based in North Carolina's Research Triangle Park, and is the inventor of StasilonTM – the FDA approved hemostatic medical textile technology approved for use both by prescription and by consumers – from which multiple hemorrhage control products are made. Building upon technologies licensed from the University of North Carolina, Entegriion's portfolio includes platelet-derived platform technologies that are being developed as topical gels and sprays for tissue repair, infusible hemostatic agents for the control of internal hemorrhage, and novel vehicles for delivery of drugs to targeted tumors and other sites of internal bleeding. For more information, visit www.entegriion.com.

###